Works matching IS 11727047 AND DT 2022 AND VI 36 AND IP 6
Results: 7
Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
- Published in:
- CNS Drugs, 2022, v. 36, n. 6, p. 633, doi. 10.1007/s40263-022-00926-0
- By:
- Publication type:
- Article
Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.
- Published in:
- CNS Drugs, 2022, v. 36, n. 6, p. 617, doi. 10.1007/s40263-022-00924-2
- By:
- Publication type:
- Article
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.
- Published in:
- CNS Drugs, 2022, v. 36, n. 6, p. 605, doi. 10.1007/s40263-022-00923-3
- By:
- Publication type:
- Article
Current Principles in the Management of Drug-Resistant Epilepsy.
- Published in:
- CNS Drugs, 2022, v. 36, n. 6, p. 555, doi. 10.1007/s40263-022-00922-4
- By:
- Publication type:
- Article
CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment.
- Published in:
- CNS Drugs, 2022, v. 36, n. 6, p. 591, doi. 10.1007/s40263-022-00921-5
- By:
- Publication type:
- Article
Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.
- Published in:
- CNS Drugs, 2022, v. 36, n. 6, p. 569, doi. 10.1007/s40263-022-00920-6
- By:
- Publication type:
- Article
Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant.
- Published in:
- CNS Drugs, 2022, v. 36, n. 6, p. 649, doi. 10.1007/s40263-022-00916-2
- By:
- Publication type:
- Article